GlaxoSmithKline

Healthcare biotech clinical research drug development pharma

GlaxoSmithKline is a science-led global healthcare company on a mission to help people do more, feel better and live longer. The Company has three businesses that research, develop and manufacture pharmaceutical medicines, vaccines and consumer healthcare products. GlaxoSmithKline manufactures products for major disease areas such as asthma, cancer, infections, diabetes and mental health.

Revenue(FY, 2017)

£30.2 B

Market capitalization(2018-07-11)

$101.9 B

Unique Visitors(FY, 2015)

1.8 M

Type

Public

Brentford, GB

Founded

2000

Size (employees)

98,462 (est)

Website

gsk.com

GlaxoSmithKline was founded in 2000 and is headquartered in Brentford, GB

Report incorrect company information

Key People/Management at GlaxoSmithKline

Emma Walmsley

Chief Executive Officer of GSK

Simon Dingemans

CFO

Hal Barron

Chief Scientific Officer and President, R&D

Roger Connor

President, Global Manufacturing & Supply

Luc Debruyne

President, Global Vaccines

James Ford

Senior Vice President and General Counsel

Report incorrect company information

GlaxoSmithKline Office Locations

Open Map View

GlaxoSmithKline has an office in Brentford

Brentford, GB (HQ)

980 Great West Rd

Show all (1)

Report incorrect company information

GlaxoSmithKline Financials and Metrics

GlaxoSmithKline Revenue

Embed Graph

GlaxoSmithKline's revenue was reported to be £30.19 b in FY, 2017 which is a 8.2% increase from the previous period.

Summary

GBP
Revenue (Q1, 2018)	7.2 b
Gross profit (Q1, 2018)	4.8 b
Gross profit margin (Q1, 2018), %	66.9%
Net income (Q1, 2018)	759 m
EBIT (Q1, 2018)	1.2 b
Market capitalization (11-Jul-2018)	101.9 b
Closing stock price (11-Jul-2018)	41.1
Cash (31-Mar-2018)	4 b
EV	115.4 b

GlaxoSmithKline's current market capitalization is $101.9 b.

Income Statement

Annual

GBP	FY, 2000	FY, 2001	FY, 2002	FY, 2003	FY, 2004	FY, 2005	FY, 2006	FY, 2007	FY, 2013	FY, 2016	FY, 2017
Revenue	18.1 b	20.5 b	21.2 b	21.4 b	20.4 b	21.7 b	23.2 b	22.7 b	26.5 b	27.9 b	30.2 b
Revenue growth, %										17%	8%
Cost of goods sold	4 b	4.7 b	4.6 b	4.5 b	4.3 b	4.8 b	5 b	5.3 b	8.6 b	9.3 b	10.3 b
Gross profit	14.1 b	15.8 b	16.6 b	16.9 b	16 b	16.9 b	18.2 b	17.4 b	17.9 b	18.6 b	19.8 b

Quarterly

GBP	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018
Revenue	7.4 b	7.3 b	7.8 b	7.2 b
Cost of goods sold	2.5 b	2.6 b	2.7 b	2.4 b
Gross profit	4.9 b	4.7 b	5.2 b	4.8 b
Gross profit Margin, %	66%	64%	66%	67%

show all

Balance Sheet

Annual

GBP	FY, 2000	FY, 2001	FY, 2002	FY, 2003	FY, 2004	FY, 2005	FY, 2006	FY, 2007	FY, 2013	FY, 2016	FY, 2017
Cash	1.3 b	716 m	1.1 b	962 m	1.2 b	4.2 b	2 b	3.4 b	5.5 b	4.9 b	3.8 b
Accounts Receivable	3.3 b	3.6 b	3.5 b	3.7 b	3.8 b	4.4 b	4.4 b	4.6 b	4 b	6 b	6 b
Inventories	2.3 b	2.1 b	2.1 b	2.1 b	2.2 b	2.2 b	2.4 b	3.1 b	3.9 b	5.1 b	5.6 b
Current Assets	11.3 b	10 b	10.7 b	12.6 b	13.6 b	13.2 b	11 b	13.6 b	15.2 b	16.7 b	15.9 b

Quarterly

GBP	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018
Cash	4.5 b	4 b	4.7 b	4 b
Accounts Receivable	6.2 b	6.2 b	6.5 b	6.1 b
Inventories	5.4 b	5.7 b	5.7 b	5.7 b
Current Assets	16.8 b	16.4 b	17.7 b	16.4 b

show all

Cash Flow

Annual

GBP	FY, 2000	FY, 2001	FY, 2002	FY, 2003	FY, 2004	FY, 2005	FY, 2006	FY, 2007	FY, 2013	FY, 2016	FY, 2017
Net Income	4.3 b	3.2 b	4 b	4.6 b	4.4 b	4.8 b	5.5 b	5.3 b	5.6 b	1.1 b	2.2 b
Depreciation and Amortization										2 b	2.9 b
Inventories										70 m	(461 m)
Accounts Payable										96 m	11 m

Quarterly

GBP	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018
Net Income	1.2 b	1.1 b	2.5 b	759 m
Cash From Operating Activities	1.1 b	2.2 b	4 b	863 m
Purchases of PP&E	(260 m)	(639 m)	(1 b)	(258 m)
Cash From Investing Activities	(199 m)	(646 m)	(1.1 b)	(371 m)